Unosi

• SAT0152 A Randomised,Doble-Blind ,Phase III Study Comparing SB2,An Infliximab Biosimilar, To the Infliximab Reference Product (Remicade) in Patients with Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy (2015-06)

  J. Choe, N. Prodanović, j. Niebrizidovski, i. Staykov, E. Dokoupilova, A. Baranauskaite, R. Yatsyshyn, M. Mekić, W. Porawska, H. Ciferska, K. Jedrichovicz-Rosiak, A. Zielinska, J. Choe, Y. Rho, J. Smolen, SAT0152 A Randomised,Doble-Blind ,Phase III Study Comparing SB2,An Infliximab Biosimilar, To the Infliximab Reference Product (Remicade) in Patients with Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy, ANNALS OF THE RHEUMATIC DISEASES, pp. 10 - 10, Jun, 2015

• FRIO162 Comparable Safety and Immunogenecity and Sustained Efficacy after Transition To SB2 (An Infliximab Biosimilar) vs Ongoing Infliximab Reference Product In Patients with Rheumatoid Arthritis: Results of Phase III Transition Stud (2016)

  J. Smolen, J. Choe, N. Prodanović, I. Staykov, E. Dokoupilova, A. Baranauskaite, R. Yatsyshyn, M. Mekić, W. Porawska, H. Ciferska, K. Jedrichovicz-Rosiak, A. Zelinska, Z. Lee, Y. Rho, FRIO162 Comparable Safety and Immunogenecity and Sustained Efficacy after Transition To SB2 (An Infliximab Biosimilar) vs Ongoing Infliximab Reference Product In Patients with Rheumatoid Arthritis: Results of Phase III Transition Stud, ANNALS OF THE RHEUMATIC DISEASES, pp. 10 - 10, 2016

• Comparing biosimilar SB2 with reference infiximab after 54 weeks of a double-bilind trail:Clinical, structural and safety results (2017)

  J. Smolen, J. Choe, N. Prodanović, J. Niebrizidovski, I. Staikov, E. Dokoupilova, A. Baranauskaite, R. Iatsishin, M. Mekić, V. Poravska, H. Ciferska, K. Jedrichovicz-Rosiak, A. Zelinska, I. Lee, I. Rho, Comparing biosimilar SB2 with reference infiximab after 54 weeks of a double-bilind trail:Clinical, structural and safety results, RHEUMATOLOGY, pp. 10 - 10, 2017